Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of the SUSTAIN 1-5 trials.
Vanita R ArodaMatthew S CapehornLouis ChaykinJuan Pablo FriasNanna L LausvigStanislava MacuraJörg LüdemannSten MadsbadJulio RosenstockOmur TabakSayeh TadayonStephen C BainPublished in: Diabetes, obesity & metabolism (2019)
Semaglutide was consistently efficacious across the continuum of diabetes care in a broad spectrum of patient subgroups with a range of clinical characteristics.